ACADIA PHARMACEUTICALS INC. Property, Plant and Equipment, Gross
ACADIA PHARMACEUTICALS INC. (ACAD) had Property, Plant and Equipment, Gross of $17.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-02-26
- 2025-12-31: Property, Plant and Equipment, Gross $17.00M.
- 2024-12-31: Property, Plant and Equipment, Gross $14.43M.
- 2023-12-31: Property, Plant and Equipment, Gross $14.17M.
- 2022-12-31: Property, Plant and Equipment, Gross $14.12M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2025-12-31 | $17.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $14.43M 10-K · filed 2026-02-26 |
| 2023-12-31 | $14.17M 10-K · filed 2025-02-27 |
| 2022-12-31 | $14.12M 10-K · filed 2024-02-28 |
| 2021-12-31 | $14.23M 10-K · filed 2023-02-28 |
| 2020-12-31 | $13.11M 10-K · filed 2022-03-01 |
| 2019-12-31 | $8.51M 10-K · filed 2021-02-25 |
| 2018-12-31 | $7.51M 10-K · filed 2020-02-27 |
| 2017-12-31 | $6.89M 10-K · filed 2019-02-27 |
| 2016-12-31 | $6.49M 10-K · filed 2018-02-27 |
| 2015-12-31 | $4.99M 10-K · filed 2017-02-28 |
| 2014-12-31 | $2.69M 10-K · filed 2016-02-29 |
| 2013-12-31 | $2.55M 10-K · filed 2015-02-26 |
| 2012-12-31 | $4.78M 10-K · filed 2014-02-27 |
| 2011-12-31 | $6.29M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |